Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

Clinical trial NCT06728865 · RECRUITING

Trial details

NCT number: NCT06728865
Sponsor: Li-kun Chen
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer (NSCLC)EGFR Mutation-Positive Lung Cancer Brain Metastases Leptomeningeal Metastases Intracranial Tumor Progression

Start date: 2024-09-04
Primary completion: 2028-02-01
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.